To investigate the clinical efficacy of osimertinib in NSCLC with various metastatic organs, we retrospectively analyzed the clinical data of 1st line treatment with osimertinib in patients with common EGFR-mutant NSCLC collected from multiple institutions. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.